Business Context and Reporting Period
Privia Health Group, Inc. filed this Form 8-K on March 22, 2022, reporting personnel changes and related executive compensation arrangements. The earliest reported event was March 16, 2022. The filing does not provide quarterly or annual financial results.
Key Financial and Operating Information
- Jeffrey S. Sherman resigned as Chief Financial Officer, principal financial officer, and principal accounting officer on March 16, 2022.
- David Mountcastle was appointed Chief Financial Officer and principal accounting officer effective March 21, 2022. He previously served as the Company’s CFO from 2014 through January 2022.
- Mountcastle’s annual base salary will be $380,000 beginning April 1, 2022.
- His annual performance bonus target is 70% of base salary, with potential increases of up to 10% annually until the target reaches 100% of base salary.
- He will receive a sign-on equity award effective April 1, 2022, consisting of stock options valued at $0.8 million and restricted stock units valued at $1.2 million. Each award vests 25% annually over four years.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material Changes Versus the Prior Comparable Period
The material change is the replacement of the Company’s CFO and principal accounting officer. Mountcastle is returning to the role after leaving it in January 2022. The filing states that Sherman’s resignation was not due to any disagreement regarding the Company’s operations, policies, practices, or accounting matters.
Outlook, Compensation, Risks, and Unusual Items
- Mountcastle is eligible for annual equity grants and compensation adjustments beginning in 2023, subject to Compensation Committee determinations.
- If terminated without cause or if he resigns for good reason, all sign-on options and restricted stock units will vest immediately, subject to the agreement’s terms.
- In such circumstances, he may receive monthly base salary and continued health benefits for 12 months, subject to execution and non-revocation of a release.
- Mountcastle agreed to a noncompetition restriction during employment and for 12 months afterward, and a nonsolicitation restriction covering clients, employees, and consultants for 24 months after termination.
- Under Sherman’s separation agreement, he acknowledged that he was not entitled to severance. The Company waived his 30-day notice period and agreed to pay his base salary for that 30-day period in lieu of continued service.
- Sherman released the Company and related parties from employment-related claims and agreed to customary nondisclosure and nondisparagement provisions.
Important Facts for Investors to Verify
- Confirm the effective dates of Sherman’s resignation and Mountcastle’s appointment, as the filing reports March 16 and March 21, 2022, respectively.
- Review Exhibit 10.1 for the precise definitions of cause, good reason, vesting acceleration, severance, and performance metrics.
- Assess the potential compensation expense and dilution from the $2.0 million sign-on equity awards and accelerated vesting provisions.
- Review Exhibit 10.2 to confirm the final payment and release terms for Sherman.
- Refer to the Company’s subsequent periodic filings for financial results, liquidity, debt, and any impact from the CFO transition.